MK-3682
Total Payments
$5.2M
Transactions
1,159
Doctors
13
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $20,688 | 10 | 0 |
| 2018 | $446,665 | 157 | 1 |
| 2017 | $4.7M | 992 | 12 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.1M | 1,081 | 99.4% |
| Travel and Lodging | $24,515 | 32 | 0.5% |
| Consulting Fee | $2,475 | 2 | 0.0% |
| Food and Beverage | $1,911 | 44 | 0.0% |
Payments by Type
Research
$5.1M
1,081 transactions
General
$28,901
78 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK-3682 MK-8408 in Subjects with Chronic Hepatitis C Virus HCV Genotype 1, 2, 3, 4, 5 or 6 Infection | Merck Sharp & Dohme Corporation | $2.0M | 0 |
| A Phase II, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682 MK-8408 in Subjects with Chronic HCV Genotype 1, 2, 3, 4, 5 or 6 Infection | Merck Sharp & Dohme Corporation | $1.8M | 0 |
| A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B MK-5172 MK-3682 MK-8408 Fixed Dose Combination FDC in Subjects with Chronic HCV GT1 or GT3 Infection who have failed a Direct Acting Antiviral Regimen | Merck Sharp & Dohme Corporation | $502,685 | 0 |
| A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3, GT4, GT5, and GT6 Infection | Merck Sharp & Dohme Corporation | $307,213 | 0 |
| A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2, and GT4 Infection | Merck Sharp & Dohme Corporation | $233,321 | 0 |
| A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682 and MK-8408 when Coadministered to Subjects with Moderate and Severe Hepatic Insufficiency | Merck Sharp & Dohme Corporation | $116,946 | 0 |
| A Four-Part Study to Evaluate the Drug-Drug Interaction of MK-3682C with Genvoya, Darunavir,Ritonavir, Atazanavir,Ritonavir, and Atripla in Healthy Subjects | Merck Sharp & Dohme Corporation | $103,101 | 0 |
| A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1 and GT2 Infection | Merck Sharp & Dohme Corporation | $40,244 | 0 |
Top Doctors Receiving Payments for MK-3682
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Richmond, VA | $5.1M | 1,081 |
| , M.D | Infectious Disease | Bronx, NY | $9,988 | 7 |
| , MD | Gastroenterology | Kailua, HI | $9,677 | 8 |
| , M.D | Gastroenterology | San Antonio, TX | $1,950 | 1 |
| , M.D | Infectious Disease | Hillsborough, NJ | $976.45 | 7 |
| , D.O | Internal Medicine | Thorndale, PA | $944.72 | 8 |
| , MD | Internal Medicine | San Francisco, CA | $838.80 | 7 |
| , MD,PHD,MBA | Gastroenterology | Newark, NJ | $803.69 | 7 |
| , MD | Internal Medicine | Houston, TX | $666.29 | 6 |
| , MD | Gastroenterology | Minneapolis, MN | $655.78 | 5 |
| , M.D | Hepatology | Orlando, FL | $651.78 | 8 |
| , MD, MPH, FACP | Hepatology | Philadelphia, PA | $625.62 | 7 |
| Joel Chua | Infectious Disease | Baltimore, MD | $598.67 | 6 |
| , M.D | Internal Medicine | Baltimore, MD | $525.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.2M
- Total Doctors 13
- Transactions 1,159
About MK-3682
MK-3682 is a drug associated with $5.2M in payments to 13 healthcare providers, recorded across 1,159 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $20,688 was paid across 10 transactions to 0 doctors.
The most common payment nature for MK-3682 is "Unspecified" ($5.1M, 99.4% of total).
MK-3682 is associated with 8 research studies, including "A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK-3682 MK-8408 in Subjects with Chronic Hepatitis C Virus HCV Genotype 1, 2, 3, 4, 5 or 6 Infection" ($2.0M).